Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of Levodopa/Carbidopa and Levodopa/Benserazide

Parkinson Disease Clinical Trial

Official title:

Effect of BIA 9-1067 at Steady-state on the Pharmacokinetics of a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa and 100/25 mg Levodopa/Benserazide in Healthy Subjects

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01533116
• Other study ID #: BIA-91067-118
• Status: Completed
• Phase: Phase 1
• First received: January 24, 2012
• Last updated: October 14, 2015
• Start date: March 2009
• Est. completion date: March 2010

Study information

• Verified date: October 2015
• Source: Bial - Portela C S.A.
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

To investigate the effect of BIA 9-1067 in steady-state conditions on the levodopa pharmacokinetics

Description:

Single centre, randomized, double-blind, gender-balanced, placebo-controlled study in 4 groups of healthy subjects

Recruitment information / eligibility

• Status: Completed
• Enrollment: 52
• Est. completion date: March 2010
• Est. primary completion date: August 2009
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 25 Years to 45 Years

Eligibility

Inclusion Criteria:

• Availability for the entire study period and willingness to adhere to the protocol requirements as evidenced by the informed consent form (ICF) duly read, signed and dated by the volunteer prior to participation in the study.

• Male or female volunteers.

• Volunteers of at least 25 years of age but not older than 45 years.

• Volunteers with body mass index (BMI) greater than or equal to 19 and below 30 kg/m2.

• Volunteers who were healthy as determined by pre-study (at screening) medical history, physical examination, vital signs, complete neurological examination and 12-lead ECG.

• Volunteers who had clinical laboratory test results judged clinically acceptable (within the laboratory's stated normal range; if not within this range, they must had been without any clinical significance) at screening and admission to first treatment period.

• Volunteers who had negative tests for hepatitis B surface antigen (HBsAg), anti-hepatitis C antibodies (HCV Ab), and Human immunodeficiency viruses -1 and -2 antibodies (HIV-1 and HIV-2 Ab) at screening.

• Volunteers who had negative screen of ethyl alcohol and drugs of abuse at screening and admission to the treatment period.

• Volunteers who were non- or ex-smokers. For the purpose of this study, an ex-smoker is defined as someone who completely stopped smoking for at least 3 months before day 1 of this study.

• Due to unknown risks and potential harm to the unborn fetus, sexually active men or women must have agreed to use a medically acceptable form of contraception throughout the study.

• If female of childbearing potential, she had a negative HCG beta serum pregnancy test at screening and admission to each treatment period.

• The informed consent form must have been signed by all volunteers, prior to their participation in the study.

Exclusion Criteria:

• Volunteers who did not conform to the above inclusion criteria, or in case of

• Volunteers who had a clinically relevant surgical history.

• Volunteers who had a clinically relevant family history.

• Volunteers who had a history of relevant atopy.

• Volunteers who had a significant infection or known inflammatory process at screening or admission to the treatment period.

• Volunteers who had acute gastrointestinal symptoms at the time of screening or admission to the treatment period (e.g., nausea, vomiting, diarrhoea, heartburn).

• Volunteers who were vegetarians, vegans or have medical dietary restrictions.

• Volunteers who could not communicate reliably with the investigator.

• Volunteers who were unlikely to co-operate with the requirements of the study.

• History of hypersensitivity to BIA 9-1067, tolcapone, entacapone, levodopa, benserazide or any related products (including excipients of the formulations) as well as severe hypersensitivity reactions (like angioedema) to any drugs.

• Presence of significant gastrointestinal, liver or kidney disease, or any other conditions known to interfere with the absorption, distribution, metabolism or excretion of drugs or known to potentiate or predispose to undesired effects.

• History of significant gastrointestinal, liver or kidney disease that may affect drug bioavailability.

• Presence or history of significant cardiovascular, pulmonary, hematologic, neurologic, psychiatric, lymphatic, musculoskeletal, genitourinary, endocrine, immunologic, dermatologic or connective tissue disease.

• Suicidal tendency, history of or disposition to seizures, state of confusion, clinically relevant psychiatric diseases.

• Presence of significant heart disease or disorder according to ECG.

• Presence of suspicious undiagnosed skin lesions or a history of melanoma.

• Previous history of Neuroleptic Malignant Syndrome (NMS) and/or nontraumatic rhabdomyolysis.

• History of significant glaucoma.

• Used of prescription medications including monoamine oxidase (MAO) inhibitors within 28 days before day 1 of the study.

• Used of over-the-counter (OTC) products within 7 days before day 1 of the study.

• Maintenance therapy with any drug, or significant history of drug dependency (drug abuse) or alcohol abuse (> 3 units of alcohol per day, intake of excessive alcohol, acute or chronic).

• Any clinically significant illness in the previous 28 days before day 1 of this study.

• Volunteers who took an Investigational Product (in another clinical trial) or donated 50 mL or more of blood in the previous 28 days before day 1 of this study.

• Poor motivation, intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with the protocol requirements or inability to cooperate adequately, inability to understand and to observe the instructions of the physician.

• Donation of 500 mL or more of blood (Canadian Blood Services, Hema-Quebec, clinical studies, etc.) in the previous 56 days before day 1 of this study.

• Positive urine screening of ethyl alcohol or drugs of abuse at admission to the treatment period.

• Any history of tuberculosis and/or prophylaxis for tuberculosis.

• Positive results to HIV, HBsAg or anti-HCV tests.

• Participation in any previous clinical study with BIA 9-1067.

• Females who were pregnant according to a positive serum pregnancy test or were lactating.

• Females of childbearing potential who refused to use an acceptable contraceptive regimen throughout the study.

Study Design

Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Parkinson Disease

Intervention

Drug:
• BIA 9-1067

• Placebo

• levodopa/carbidopa

• levodopa/benserazide

Locations

Country	Name	City	State
Canada	Algorithme Pharma Inc.	Mount-Royal	Quebec

Sponsors (1)

Lead Sponsor	Collaborator
Bial - Portela C S.A.

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Cmax - Maximum Plasma Concentration	Cmax - maximum plasma concentration Cmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Cmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®	pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h	No
Primary	Tmax - Time to Maximum Plasma Concentration	Tmax - time to maximum plasma concentration Tmax (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® Tmax (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®	pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h	No
Primary	AUC0-t - Area Under the Plasma Concentration-time Curve to Last Measurable Time Point	AUC0-t - area under the plasma concentration-time curve from time 0 to last observed concentration 3-OMD - 3-O-methyl-dopa - metabolite of L-DOPA (levodopa) AUC0-t (Levodopa) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (3-OMD) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa® AUC0-t (BIA 9-1067) Sinemet® or Prolopa® - following administration of Sinemet® or Prolopa®	pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h	No
Primary	tEmax - Time of Occurrence of Maximum Observed Effect on S-COMT Activity	tEmax - time of occurrence of maximum observed effect on S-COMT activity COMT - Catechol-O-Methyltransferase	pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h	No
Primary	AUEC0-24 - Area Under the Effect-time Curve (AUEC) to 24 h Post-dose	AUEC0-24 - Area under the effect-time curve (AUEC) to 24 h post-dose.	pre-dose and at the following times post-dose: 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, 16 and 24 h	No